Q3179251 (Q3179251): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Diabetic retinopathy is one of the main causes of irreversible blindness in the world whose current treatment is limited to the advanced stages of the disease and is based on laser coagulation of the retina in case of ischemia or intravitreal antiangiogenic or steroid therapy in case of macular edema. None of these treatments are used in less advanced phases to stop progression, nor in many cases produce a complete, definitive and stable improve...) |
||||||||||||||
| Property / summary | |||||||||||||||
Diabetic retinopathy is one of the main causes of irreversible blindness in the world whose current treatment is limited to the advanced stages of the disease and is based on laser coagulation of the retina in case of ischemia or intravitreal antiangiogenic or steroid therapy in case of macular edema. None of these treatments are used in less advanced phases to stop progression, nor in many cases produce a complete, definitive and stable improvement. The results obtained by the research team following the experimental intravitreal injection of a solution containing lysine acetyl salicylate in an animal model of diabetic retinopathy show the presence of greater vascular integrity and reduced inflammation and vascular permeability in those animals receiving treatment. Based on the results obtained, we understand that the intravitreal solution for injection of acetyl salicylate lysine should complete its pre-clinical development with a tolerance, toxicity and safety test prior to use in humans. It is a novel treatment, original and never before used for the treatment of this pathology (Patent PCT/ES2016/070396, priority date 26/05/2015. Intravitreal lysine acetylsalicylate as a treatment of diabetic retinopathy). Its ability to preserve vessels and tissue homeostasis make it a tool capable of acting in less advanced phases of diabetic retinopathy and delaying its evolution where no drug is able to do so at this time. (English) | |||||||||||||||
| Property / summary: Diabetic retinopathy is one of the main causes of irreversible blindness in the world whose current treatment is limited to the advanced stages of the disease and is based on laser coagulation of the retina in case of ischemia or intravitreal antiangiogenic or steroid therapy in case of macular edema. None of these treatments are used in less advanced phases to stop progression, nor in many cases produce a complete, definitive and stable improvement. The results obtained by the research team following the experimental intravitreal injection of a solution containing lysine acetyl salicylate in an animal model of diabetic retinopathy show the presence of greater vascular integrity and reduced inflammation and vascular permeability in those animals receiving treatment. Based on the results obtained, we understand that the intravitreal solution for injection of acetyl salicylate lysine should complete its pre-clinical development with a tolerance, toxicity and safety test prior to use in humans. It is a novel treatment, original and never before used for the treatment of this pathology (Patent PCT/ES2016/070396, priority date 26/05/2015. Intravitreal lysine acetylsalicylate as a treatment of diabetic retinopathy). Its ability to preserve vessels and tissue homeostasis make it a tool capable of acting in less advanced phases of diabetic retinopathy and delaying its evolution where no drug is able to do so at this time. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Diabetic retinopathy is one of the main causes of irreversible blindness in the world whose current treatment is limited to the advanced stages of the disease and is based on laser coagulation of the retina in case of ischemia or intravitreal antiangiogenic or steroid therapy in case of macular edema. None of these treatments are used in less advanced phases to stop progression, nor in many cases produce a complete, definitive and stable improvement. The results obtained by the research team following the experimental intravitreal injection of a solution containing lysine acetyl salicylate in an animal model of diabetic retinopathy show the presence of greater vascular integrity and reduced inflammation and vascular permeability in those animals receiving treatment. Based on the results obtained, we understand that the intravitreal solution for injection of acetyl salicylate lysine should complete its pre-clinical development with a tolerance, toxicity and safety test prior to use in humans. It is a novel treatment, original and never before used for the treatment of this pathology (Patent PCT/ES2016/070396, priority date 26/05/2015. Intravitreal lysine acetylsalicylate as a treatment of diabetic retinopathy). Its ability to preserve vessels and tissue homeostasis make it a tool capable of acting in less advanced phases of diabetic retinopathy and delaying its evolution where no drug is able to do so at this time. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 19:02, 12 October 2021
Project Q3179251 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3179251 in Spain |
Statements
22,750.0 Euro
0 references
45,500.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
10 December 2019
0 references
FUNDACION PARA EL FOMENTO DE LA INV. SANITARIA Y BIOMEDICA DE LA COMUNIDAD VALENCIANA (FISABIO)
0 references
38°15'55.19"N, 0°41'55.82"W
0 references
03065
0 references
La retinopatía diabética supone una de las principales causas de ceguera irreversible en el mundo cuyo tratamiento actual se limita a las fases avanzadas de la enfermedad y se basa en la coagulación con láser de la retina en caso de isquemia o en la terapia intravítrea antiangiogénica y/o esteroidea en caso de edema macular. Ninguno de estos tratamientos se usa en fases menos avanzadas para detener la progresión, ni tampoco producen en muchos casos una mejoría completa, definitiva y estable. Los resultados obtenidos por el equipo investigador tras la inyección intravítrea experimental de una solución que contiene acetil salicilato de lisina en un modelo animal de retinopatía diabética evidencian la presencia de una mayor integridad vascular y de una reducción de la inflamación y de la permeabilidad vascular en aquellos animales que recibieron el tratamiento. En base a los resultados obtenidos entendemos que la solución inyectable vía intravítrea de acetil salicilato de lisina debe completar su desarrollo pre-clínico con un ensayo de tolerancia, toxicidad y seguridad del mismo previo a su utilización en humanos. Se trata de un tratamiento novedoso, original y nunca antes utilizado para el tratamiento de esta patología (Patente PCT/ES2016/070396, fecha de prioridad 26/05/2015. Acetilsalicilato de lisina intravítreo como tratamiento de la retinopatía diabética). Su capacidad de preservar los vasos y la homeostasis de los tejidos le convierten en una herramienta capaz de actuar en fases menos avanzadas de la retinopatía diabética y retrasar su evolución dónde ningún fármaco es capaz de hacerlo en este momento. (Spanish)
0 references
Diabetic retinopathy is one of the main causes of irreversible blindness in the world whose current treatment is limited to the advanced stages of the disease and is based on laser coagulation of the retina in case of ischemia or intravitreal antiangiogenic or steroid therapy in case of macular edema. None of these treatments are used in less advanced phases to stop progression, nor in many cases produce a complete, definitive and stable improvement. The results obtained by the research team following the experimental intravitreal injection of a solution containing lysine acetyl salicylate in an animal model of diabetic retinopathy show the presence of greater vascular integrity and reduced inflammation and vascular permeability in those animals receiving treatment. Based on the results obtained, we understand that the intravitreal solution for injection of acetyl salicylate lysine should complete its pre-clinical development with a tolerance, toxicity and safety test prior to use in humans. It is a novel treatment, original and never before used for the treatment of this pathology (Patent PCT/ES2016/070396, priority date 26/05/2015. Intravitreal lysine acetylsalicylate as a treatment of diabetic retinopathy). Its ability to preserve vessels and tissue homeostasis make it a tool capable of acting in less advanced phases of diabetic retinopathy and delaying its evolution where no drug is able to do so at this time. (English)
12 October 2021
0 references
Elche/Elx
0 references
Identifiers
DTS17_00169
0 references